Trial Profile
A Multi-centre, Open-label, Parallel-group Trial Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 08 Dec 2017 Results of a study assessing effect of hepatic impairment on Semaglutide exposure, presented at the 2017 Congress of the International Diabetes Federation
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 04 Apr 2017 Primary endpoint (Area under the semaglutide plasma concentration-time curve from time zero to infinity (AUC0-infinity)) has been met, according to results presented at The 99th Annual Meeting of the Endocrine Society.